Defining glioblastoma resectability through the wisdom of the crowd: A proof-of-principle study

Neurosurgery

Volumn 80, Issue 4, 2017, Pages 590-601

  Sonabend, Adam M ^a   Zacharia, Brad E ^b   Cloney, Michael B ^a   Sonabend, Aarón ^c   Showers, Christopher ^a   Ebiana, Victoria ^a   Nazarian, Matthew ^a   Swanson, Kristin R ^d   Baldock, Anne ^e   Brem, Henry ^f   Bruce, Jeffrey N ^a   Butler, William ^g   Cahill, Daniel P ^g   Carter, Bob ^h   Orringer, Daniel A ⁱ   Roberts, David W ^j   Sagher, Oren ^k   Sanai, Nader ^l   Schwartz, Theodore H ^m   Silbergeld, Daniel L ⁿ   Sisti, Michael B ^a   Thompson, Reid C ^o   Waziri, Allen E ^p   Ghogawala, Zoher ^p   McKhann, Guy ^a   more..

^a Columbia University Medical Center ^*  (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

ⁱ UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^j DARTMOUTH COLLEGE   (United States)

^k BARROW NEUROLOGICAL INSTITUTE   (United States)

^l NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^m UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

ⁿ VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^o Inova Neuroscience Institute   (United States)

^p LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

more..

Author keywords

Crowdsourcing; EOR; Extent of resection; Glioblastoma; Glioma; Resectability

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SURGERY; CLINICAL ARTICLE; CROWDSOURCING; DIGITAL IMAGING AND COMMUNICATIONS IN MEDICINE; FEMALE; GLIOBLASTOMA; HUMAN; MALE; MIDDLE AGED; NEUROSURGEON; NUCLEAR MAGNETIC RESONANCE IMAGING; PILOT STUDY; PRIORITY JOURNAL; PROOF OF CONCEPT; YOUNG ADULT; ADOLESCENT; BRAIN TUMOR; DIAGNOSTIC IMAGING; MINIMAL RESIDUAL DISEASE; NEUROSURGERY; PATHOLOGY; PROCEDURES; BRAIN STEM; CONTRAST ENHANCEMENT; CORPUS CALLOSUM; MIDDLE CEREBRAL ARTERY; NEUROANATOMY; NEUROIMAGING; THALAMUS; VISUAL CORTEX;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; FEMALE; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; NEUROSURGICAL PROCEDURES; PILOT PROJECTS;

EID: 84981294602     PISSN: 0148396X     EISSN: 15244040     Source Type: Journal    
DOI: 10.1227/NEU.0000000000001374     Document Type: Article

References (47)

1. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, survival. J Neurosurg. 2001;95(2):190-198.
2. Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS An extent of resection threshold for newly diagnosed glioblastomas. JNeurosurg. 2011;115(1):3-8.
3. Keles GE, Anderson B, Berger MS. The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol. 1999;52(4):371-379.
4. Lamborn KR, Chang SM, Prados MD. Prognostic factors for survival of patients with glioblastoma: Recursive partitioning analysis. Neuro Oncol. 2004; 6(3):227-235.
5. Shibamoto Y, Yamashita J, Takahashi M, Yamasaki T, Kikuchi H, Abe M. Supratentorial malignant glioma: An analysis of radiation therapy in 178 cases. Radiother Oncol. 1990;18(1):9-17.
6. Simpson J.R., Horton J, Scott C, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: Results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys. 1993;26(2):239-244.
7. Jeremic B, Grujicic D, Antunovic V, Djuric L, Stojanovic M, Shibamoto Y. Influence of extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach. J Neurooncol. 1994;21(2):177-185.
8. Barker FG, Prados MD, Chang SM, et al. Radiation response and survival time in patients with glioblastoma multiforme. J Neurosurg. 1996;84(3):442-448.
9. Ushio Y, Kochi M, Hamada J, Kai Y, Nakamura H. Effect of surgical removal on survival and quality of life in patients with supratentorial glioblastoma. Neurol Med Chir (Tokyo). 2005;45(9):454-460; discussion 460-451.
10. Stark AM, Nabavi A, Mehdorn HM, Blomer U. Glioblastoma multiformereport of 267 cases treated at a single institution. Surg Neurol. 2005;63(2):162-169; discussion 169.
11. Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: Identification of and adjustment for bias. Neurosurgery. 2008;62(3):564-576; discussion 564-576.
12. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery. 2008;62(4):753-764; discussion 264-756.
13. Carrabba G, Fava E, Giussani C, et al. Cortical and subcortical motormapping in rolandic and perirolandic glioma surgery: Impact on postoperative morbidity and extent of resection. J Neurosurg Sci. 2007;51(2):45-51.
14. Woodward DE, Cook J, Tracqui P, Cruywagen GC, Murray JD, Alvord EC. A mathematical model of glioma growth: The effect of extent of surgical resection. Cell Prolif. 1996;29(6):269-288.
15. Iacoangeli M, Roselli R, Prezioso A, Scerrati M, Rossi GF. Staging of supratentorial hemispheric glioma using tumour extension, histopathological grade and extent of surgical resection. Br J Surg. 1993;80(9):1130-1133.
16. Winger MJ, Macdonald DR, Cairncross JG. Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma. J Neurosurg. 1989;71(4):487-493.
17. Ammirati M, Vick N, Liao YL, Ciric I, Mikhael M. Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas. Neurosurgery. 1987;21(2):201-206.
18. Ciric I, Ammirati M, Vick N, Mikhael M. Supratentorial gliomas: Surgical considerations and immediate postoperative results. Gross total resection versus partial resection. Neurosurgery. 1987;21(1):21-26.
19. Kiwit JC, Floeth FW, Bock WJ. Survival in malignant glioma: Analysis of prognostic factors with special regard to cytoreductive surgery. Zentralbl Neurochir. 1996;57(2):76-88.
20. Walker MD, Alexander E, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978;49(3):333-343.
21. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
22. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-466.
23. Vredenburgh JJ, Desjardins A, Herndon JE, et al.. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25(30):4722-4729.
24. Cohen MH, Shen YL, Keegan P, Pazdur R. FDA drug approval summary: Bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist. 2009;14(11):1131-1138.
25. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5(2):79-88.
26. Brem H, Ewend MG, Piantadosi S, Greenhoot J, Burger PC, Sisti M. The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: Phase I trial. J Neurooncol. 1995;26(2):111-123.
27. Sawaya R, Hammoud M, Schoppa D, et al. Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery. 1998;42(5):1044-1055; discussion 1055-1046.
28. Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol. 2010;28(24):3838-3843.
29. Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: Limiting factors, perception of resectability, effect on survival. J Neurosurg. 2012;117(5):851-859.
30. Sims MH, Fagnano M, Halterman JS, Halterman MW. Provider impressions of the use of a mobile crowdsourcing app in medical practice. Health Informatics J. 2016;22(2):221-231.
31. Della Mea V, Maddalena E, Mizzaro S, Machin P, Beltrami CA. Preliminary results from a crowdsourcing experiment in immunohistochemistry. Diagn Pathol. 2014;9(suppl 1):S6.
32. Brady CJ, Villanti AC, Pearson JL, Kirchner TR, Gupta OP, Shah CP. Rapid grading of fundus photographs for diabetic retinopathy using crowdsourcing.JMed Internet Res. 2014;16(10):e233.
33. Irshad H, Montaser-Kouhsari L, Waltz G, et al. Crowdsourcing image annotation for nucleus detection and segmentation in computational pathology: Evaluating experts, automated methods, the crowd. Pac Symp Biocomput. 2015;20:294-305.
34. Mitry D, Peto T, Hayat S, et al. Crowdsourcing as a screening tool to detect clinical features of glaucomatous optic neuropathy from digital photography. PLoS One. 2015;10(2):e0117401.
35. Mitry D, Peto T, Hayat S, Morgan JE, Khaw KT, Foster PJ. Crowdsourcing as a novel technique for retinal fundus photography classification: Analysis of images in the EPICNorfolk cohort on behalf of theUKBiobank Eye andVision Consortium. PLoS One. 2013;8(8):e71154.
36. Ghogawala Z, Coumans JV, Benzel EC, Stabile LM, Barker FG. Ventral versus dorsal decompression for cervical spondylotic myelopathy: Surgeons' assessment of eligibility for randomization in a proposed randomized controlled trial: Results of a survey of the Cervical Spine Research Society. Spine (Phila Pa 1976). 2007;32(4):429-436.
37. Swanson KR, Chakraborty G, Wang C.H., et al. Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas. J Nucl Med. 2009;50(1):36-44.
38. Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in adults.JNeurosurg. 2008;109(5): 817-824.
39. Mor V, Laliberte L, Morris JN, Wiemann M. The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer. 1984;53(9):2002-2007.
40. Senft C, Bink A, Franz K, Vatter H, Gasser T, Seifert V. Intraoperative MRI guidance and extent of resection in glioma surgery: A randomised, controlled trial. Lancet Oncol. 2011;12(11):997-1003.
41. Senft C, Bink A, Heckelmann M, Gasser T, Seifert V. Glioma extent of resection and ultra-low-field iMRI: Interim analysis of a prospective randomized trial. Acta Neurochir Suppl. 2011;109:49-53.
42. Senft C, Seifert V, Hermann E, Franz K, Gasser T. Usefulness of intraoperative ultra low-field magnetic resonance imaging in glioma surgery. Neurosurgery. 2008; 63(4 Suppl 2):257-266; discussion 266-257.
43. Hatiboglu MA, Weinberg JS, Suki D, et al. Impact of intraoperative high-field magnetic resonance imaging guidance on glioma surgery: A prospective volumetric analysis. Neurosurgery. 2009;64(6):1073-1081; discussion 1081.
44. Kourou K, Exarchos TP, Exarchos K.P., Karamouzis MV, Fotiadis DI. Machine learning applications in cancer prognosis and prediction. Comput Struct Biotechnol J. 2015;13:8-17.
45. Enshaei A, Robson CN, Edmondson RJ. Artificial intelligence systems as prognostic and predictive tools in Ovarian Cancer. Ann Surg Oncol. 2015;22 (12):3970-3975.
46. Beiko J, Suki D, Hess KR, et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol. 2014;16(1):81-91.
47. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. New Engl J Med. 2009;360(8):765-773.